High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission

Neoplasma

Volumn 55, Issue 3, 2008, Pages 215-221

  Papajik, T ^a   Raida, L ^a   Faber, E ^a   Vondrakova, J ^a   Prochazka, V ^a   Kubova, Z ^a   Skoumalova, I ^a   Jarosova, M ^a   Kucerova, L ^a   Tichy, M ^a   Paucek, B ^a   Myslivecek, M ^a   Neoral, C ^a   Oral, I ^b   Jarkovsky, J ^c   Dusek, L ^c   Indrak, K ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b Hranice Hospital   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Autologous transplantation; Diffuse large B cell lymphoma; Rituximab; Survival

Indexed keywords

BETA 2 MICROGLOBULIN; BLEOMYCIN; CARMUSTINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; LACTATE DEHYDROGENASE; MELPHALAN; MESNA; METHOTREXATE; MITOXANTRONE; RITUXIMAB; THYMIDINE KINASE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BRAIN LYMPHOMA; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CONTINUOUS INFUSION; DIFFUSE LARGE B CELL LYMPHOMA; DRUG MEGADOSE; DRUG RESPONSE; ENZYME BLOOD LEVEL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTENSIVE CARE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; SURVIVAL TIME; THERAPY EFFECT; TREATMENT RESPONSE; AUTOTRANSPLANTATION; DISEASE FREE SURVIVAL; EVALUATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; REMISSION; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 49149100562     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. HARRIS N.L., JAFFE E.S., STEIN H., et al.: A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 1994; 84: 1361-1392. (Pubitemid 24273002)
2. HARRIS N.L., JAFFE E.S., DIEBOLD J., et al.: World Health Organization classification of neoplastic disease of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee Meeting - Airlie House, Virginia, November 1997. J.Clin.Oncol. 1999; 17: 3835-3849.
3. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 329: 987-994.
4. SUKI S., SWAN F., TUCKER S., et al: Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk. Lymphoma 1995; 18: 87-92.
5. BEA S., COLOMO L., LÓPEZ-GUILLERMO A., et al.: Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. J. Clin. Oncol. 2004; 22: 3498-3506.
6. COLOMO L., LÓPEZ-GUILLERMO A., PERALES M., et al.: Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.
7. van IMHOFF G.W., BOERMA E.J., van der HOLT B., et al.: Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J. Clin. Oncol. 2006; 24: 4135-4142.
8. COIFFIER B., GISSELBRECHT C., HERBRECHT R., et al.: LNH-84: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J. Clin. Oncol. 1988; 6: 1832-1837.
9. 18F/FDG-PET a valid alternative to conventional diagnostic methods? J. Clin. Oncol. 2001; 19: 414-419.
10. PHILIP T., GUGLIELMI C., HAGENBEEK A., et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med., 1995; 333: 1540-1545.
11. HAIOUN C., LEPAGE E., GISSELBRECHT C., et al.: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Update results of the prospective study LNH87-2. J. Clin. Oncol. 1997; 15: 1131-1137.
12. HAIOUN C., LEPAGE E., GISSELBRECHT C., et al.: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - A Groupe d'Etude des Lymphomes de l'Adulte Study. J. Clin. Oncol. 2000; 18: 3025-3030.
13. MILPIED N., DECONINCK E., GAILLARD F., et al.: Initial Treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N. Engl. J. Med. 2004; 350: 1287-1295.
14. FEUGIER P., VAN HOOF A., SEBBAN C., et al.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 2005; 23: 4117-4126.
15. PFREUNDSCHUH M.G., TRUMPER L., OSTERBORG A., et al.: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379-391
16. MILPIED N., LAMY T., CASASSUS P., et al.: Front-line high-dose chemotherapy (HDT) combined with rituximab for adults with aggressive large B cell lymphoma (DLBCL). A pilot study by the GOELAMS. J. Clin. Oncol. 2004; 22 (Suppl.): 6662.
17. CORTELAZZO S., ROSSI A., CARLOTTI E., et al.: The Addition of Rituximab to High Dose Sequential Chemotherapy (HDS) Programs with Autologous Transplantation Significantly Improves the Outcome of Patients with Refractory or Relapsed B-Cell Non Hodgkin's Lymphoma. Blood 2005; 106: 2084a.
18. VITOLO U., CABRAS M. G., ROSSI G., et al.: Rituximab as Adjuvant to Dose-Dense and High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as First Line Treatment in Stage III-IV Diffuse Large B-Cell Lymphoma (DLBCL) at Poor Prognosis: Final Analysis of Phase II GIMURELL Trial. Blood 2006; 108: 329a.
19. LISTER T.A., CROWTHER D., SUTCLIFFE S.B., et al.: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J. Clin. Oncol. 1989; 7: 1630-1636.
20. CHESON B.D., HORNING S.J., COIFFIER B., et al.: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomnas. J. Clin. Oncol. 1999; 17: 1244-1253.
21. KAPLAN, E.L., MEIER, P.: Nonparametric estimation from incomplete observations. Journal of American Statistical Association 1958; 53: 457-481.
22. COX, D. R.: Regression Models and Life Tables (with Discussion). Journal of the Royal Statistical Society, Series B 1972; 34: 187-220.
23. FISCHER R.I., GAYNOR E.R., DAHLBERG S., et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 328: 1002-1006.
24. TILLY H., LEPAGE E., COIFFIER B., et al.: Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284-4289.
25. REYES F., LEPAGE E., GANEM G., et al.: ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N. Engl. J. Med. 2005; 352: 1197-1205.
26. REYES F., LEPAGE E., MOREL P., et al.: Failure of first-line, inductive high-dose chemotherapy (HDC) in poor risk patients (PTS) with aggressive lymphoma: Updated results of the randomized LNH 93-103 study. Blood 1997; 90 (Suppl. 1): S94a.
27. KAISER U., UEBELACKER I., HAVEMANN K., et al.: High dose chemotherapy with autologous stem cell transplantation in high-grade NHL: First analysis of a randomized multicenter study. Bone Marrow Transpl. 1998; 21 (Suppl. 1): S 177.
28. SHIPP M.A., ABELOFF M.D., ANTMAN K.H. et al.: International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J. Clin. Oncol. 1999; 17: 423-429.
29. PAPAJIK T., VONDRAKOVA J., RAIDA L., et al.: Assessment of selected prognostic factors in patients with non-Hodgkin's lymphoma. Klin. Onkologie 2001; 14: 102-105 (in Czech).
30. MOUNIER N., GISSELBRECHT C., BRIÉRE J., et al.: Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: A cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 2004; 22: 2826-2834.
31. STAUDT L.M.: Molecular diagnosis of the hematologic cancers. N. Engl. J. Med. 2003; 348: 1777-1785.
32. KRISHNAN A., NADEMANE A., FUNG H., et al.: Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation? Biol. Blood Bone Marrow Transplant. 2006; 12: 641-647.
33. GLASS B., KLOESS M., REISER M., et al.: Dose Escalated CHOP + Etoposide Followed by Repetitive Autologous Stem Cell Transplantation (MegaCHOEP) with or without Rituximab for Primary Treatment of Aggressive NHL. Blood 2005; 106: 1492a.